Orencia Abatacept Drug Global Market Report 2025

The orencia abatacept drug market size has grown strongly in recent years. It will grow from $3.71 billion in 2024 to $3.96 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune diseases, rising awareness of biologic therapies, expanding indications for abatacept, growing healthcare expenditure, supportive regulatory approvals, and enhanced market penetration through strategic collaborations.

The orencia abatacept drug market size is expected to see strong growth in the next few years. It will grow to $5.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to expanding therapeutic indications, the rising adoption of combination therapies, increased access to healthcare, favorable reimbursement policies, ongoing clinical trials exploring novel applications, and growing patient awareness of advanced treatment options. Key trends expected during this period include improved formulation, advancements in subcutaneous delivery methods, the integration of digital health solutions for monitoring, expanded therapeutic indications, and progress in clinical trials.

The growing incidence of autoimmune diseases is expected to drive the expansion of the Orencia (abatacept) drug market in the coming years. Autoimmune diseases arise when the immune system mistakenly attacks the body's own healthy cells and tissues. Several factors contribute to the increasing prevalence of these diseases, including genetic predisposition, environmental influences, and lifestyle changes. Orencia (abatacept) helps patients with autoimmune disorders by selectively modulating T-cell activation, reducing inflammation, and preventing joint damage. This supports disease management, enhances quality of life, and reduces reliance on other immunosuppressive treatments for conditions such as rheumatoid arthritis and psoriatic arthritis. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. As a result, the increasing prevalence of autoimmune diseases is fueling the growth of the Orencia (abatacept) drug market.

The rise of personalized medicine is further contributing to the expansion of the Orencia (abatacept) drug market. Personalized medicine is an approach that customizes treatment and healthcare strategies based on an individual’s genetic makeup, environment, and lifestyle, ensuring more precise and effective outcomes. The growing adoption of personalized medicine is driven by advancements in genomic technologies, a deeper understanding of molecular biology, the increased availability of precision diagnostic tools, and the demand for targeted therapies that enhance patient outcomes while minimizing side effects. Orencia (abatacept) supports personalized medicine by providing targeted immunotherapy that specifically modulates T-cell activation, allowing healthcare providers to tailor treatment plans based on disease severity, patient profiles, and individual responses to therapy. For example, in 2023, the Personalized Medicine Coalition, a US-based representative organization, reported that in 2022, the FDA approved personalized medicines for 34% of new drugs, with at least 25% of new drug approvals in each of the previous eight years attributed to personalized medicine. Consequently, the growing adoption of personalized medicine is driving the demand for Orencia (abatacept).

In January 2023, Lotte Biologics Co. Ltd., a South Korea-based biotechnology company, acquired a biopharmaceutical production facility in New York from Bristol Myers Squibb Company for $160 million. This acquisition is aimed at expanding Lotte Biologics’ manufacturing capabilities and strengthening its contract development and manufacturing organization (CDMO) services. Bristol Myers Squibb Company, a US-based pharmaceutical company, specializes in developing biopharmaceutical products, including Orencia (abatacept).

The key player in the orencia abatacept drug market is Bristol-Myers Squibb Company.

North America was the largest region in the orencia abatacept drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in orencia abatacept drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the orencia abatacept drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Orencia (abatacept) is a biologic drug prescribed for autoimmune disorders that works by inhibiting the activation of T-cells. As a selective co-stimulation modulator, it helps reduce immune system overactivity, thereby lowering inflammation and protecting joints from damage.

The primary product types in the Orencia (abatacept) drug market include subcutaneous injections and intravenous infusions. A subcutaneous injection involves administering the medication into the tissue just beneath the skin using a needle. This drug is used for various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and others. It is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and other distribution networks.

The orencia abatacept drug market research report is one of a series of new reports that provides orencia abatacept drug market statistics, including the orencia abatacept drug industry's global market size, regional shares, competitors with a orencia abatacept drug market share, detailed orencia abatacept drug market segments, market trends and opportunities, and any further data you may need to thrive in the orencia abatacept drug industry. This orencia abatacept drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The orencia abatacept drug consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.